These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9010152)

  • 1. Thrombopoietin--clinically realized?
    Levin J
    N Engl J Med; 1997 Feb; 336(6):434-6. PubMed ID: 9010152
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of thrombopoietin and related Mpl-ligands on transfusion medicine.
    Farese AM; Schiffer CA; MacVittie TJ
    Transfus Med Rev; 1997 Oct; 11(4):243-55. PubMed ID: 9345706
    [No Abstract]   [Full Text] [Related]  

  • 3. Platelet growth factors: potential impact on transfusion medicine.
    Kuter DJ; Cebon J; Harker LA; Petz LD; McCullough J
    Transfusion; 1999 Mar; 39(3):321-32. PubMed ID: 10204598
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombopoietin: platelets on demand?
    Kaushansky K
    Ann Intern Med; 1997 May; 126(9):731-3. PubMed ID: 9139560
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
    Fanucchi M; Glaspy J; Crawford J; Garst J; Figlin R; Sheridan W; Menchaca D; Tomita D; Ozer H; Harker L
    N Engl J Med; 1997 Feb; 336(6):404-9. PubMed ID: 9010146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombopoietin.
    Kaushansky K
    N Engl J Med; 1998 Sep; 339(11):746-54. PubMed ID: 9731092
    [No Abstract]   [Full Text] [Related]  

  • 7. What's new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists.
    Newland A
    Med Princ Pract; 2011; 20(4):301-2. PubMed ID: 21576988
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.
    Nakamura M; Toombs CF; Duarte IG; Ronson RS; Schmarkey LS; Katzmark SL; Robinson J; Dillehay DL; Vinten-Johansen J; Guyton RA
    Ann Thorac Surg; 1998 Oct; 66(4):1216-23. PubMed ID: 9800809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic potential of thrombopoietin].
    Geissler K
    Wien Klin Wochenschr; 2000 Oct; 112(19):829-34. PubMed ID: 11098533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin: biology and potential clinical applications.
    Prow D; Vadhan-Raj S
    Oncology (Williston Park); 1998 Nov; 12(11):1597-604, 1607-8; discussion 1611-4. PubMed ID: 9834938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of the Kasabach-Merritt syndrome with pegylated recombinant human megakaryocyte growth and development factor in mice: elevated platelet counts, prolonged survival, and tumor growth inhibition.
    Verheul HM; Panigrahy D; Flynn E; Pinedo HM; D'Amato RJ
    Pediatr Res; 1999 Nov; 46(5):562-5. PubMed ID: 10541319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
    Taylor N; Melchardt T; Grundbichler M; Strasser M; Egle A; Greil R
    Ann Hematol; 2013 Jul; 92(7):1001-2. PubMed ID: 23269533
    [No Abstract]   [Full Text] [Related]  

  • 13. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study.
    Wu Q; Ren J; Wu X; Wang G; Gu G; Liu S; Wu Y; Hu D; Zhao Y; Li J
    J Crit Care; 2014 Jun; 29(3):362-6. PubMed ID: 24405656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
    Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the potential for thrombopoietic agents in acute leukemia?
    Kuter DJ
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):553-8. PubMed ID: 22127320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
    Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
    Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical results with MGDF].
    Martín G
    Sangre (Barc); 1997 Apr; 42 Suppl 1():61. PubMed ID: 9381307
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
    Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
    Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.